Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04956198 · ClinicalTrials.gov registry record
Drug Sensitivity and Mutation Profiling
A clinical trial, sponsored by Florida International University.
- Completed
- Registry status
- 14
- Enrollment target
NCT04956198: Completed study, sponsored by Florida International University.
NCT04956198 is a clinical trial that has completed, run by Florida International University. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04956198 has completed, sponsored by Florida International University.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
This study is a prospective, non-randomized observational study. Freshly isolated tumor cells will be tested for chemosensitivity to the standard of care drugs as single agents and in combinations using state-of-the-art viability assay designed for ex-vivo high-throughput drug sensitivity testing (DST). In addition, the genetic profile of the tumor will be obtained from the medical records and correlated with drug response.
Primary Outcome
Response to therapy (RTT): an event of achieving "partial response" or "complete response" during the study period, based on the best response of the corresponding enrolled patient.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-11-17 |
| Est. Completion | 2022-12-31 |
What the finished NCT04956198 record still lists
NCT04956198 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04956198 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04956198 about?
NCT04956198 is a clinical study titled "Drug Sensitivity and Mutation Profiling". This study is a prospective, non-randomized observational study. Freshly isolated tumor cells will be tested for chemosensitivity to the standard of care drugs as single agents and in combinations using state-of-the-art viability assay designed for ex-vivo high-throughput drug sensitivity testing (D...
What is the current status of trial NCT04956198?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2020-11-17. Estimated completion is 2022-12-31.
Who is sponsoring clinical trial NCT04956198?
This trial is sponsored by Florida International University, which has 89 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy